DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit


Werte in diesem Artikel
Aktien

64.20 EUR 1.20 EUR 1.90 %

NEW YORK, Aug. 23, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an "international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management." A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2024.

Rosen Law Firm, P.A. Logo

If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

To join the DexCom class action, go to https://rosenlegal.com/submit-form/?case_id=28133 or call Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, during the Class Period, on July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on DexCom's perceived growth potential. When the true details entered the market, the lawsuit claims that investors suffered damages.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Rosen Law: Some law firms issuing releases about this matter do not actually litigate securities class actions; Rosen Law Firm does. A recognized leader in shareholder rights litigation, the attorneys and staff of Rosen Law Firm have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing. Since our inception, we have obtained over $1 billion for shareholders.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      case@rosenlegal.com
      www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dxcm-investors-have-opportunity-to-lead-dexcom-inc-securities-fraud-lawsuit-302229828.html

SOURCE THE ROSEN LAW FIRM, P. A.

Aktuelle DexCom Aktie News

Werbung

DexCom Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DexCom nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
02.08.18 DexCom Buy Canaccord Adams
03.05.18 DexCom Buy Canaccord Adams
23.03.18 DexCom Outperform Robert W. Baird & Co. Incorporated
28.09.17 DexCom Outperform Wedbush Morgan Securities Inc.
15.09.17 DexCom Equal Weight Barclays Capital